Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464903 · ClinicalTrials.gov registry record
Study of ALS Reversals 2: Genetic Analyses
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 26
- Enrollment target
NCT03464903: Completed study, sponsored by Duke University.
NCT03464903 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03464903 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA reversal is because of certain changes in the genetic code.
Primary Outcome
comparison of genes of participants with ALS reversals to genes of more typically progressive patients with ALS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-22 |
| Est. Completion | 2023-12-01 |
What the finished NCT03464903 record still lists
NCT03464903 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03464903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03464903 about?
NCT03464903 is a clinical study titled "Study of ALS Reversals 2: Genetic Analyses". The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA reversal is because of certain...
What is the current status of trial NCT03464903?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2018-06-22. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT03464903?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI